Inovio Pharma (INO) Reports Interim Phase 1 Data For INO-4800 Vaccine for COVID-19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. CRWV
2. NVDA
3. SPY
4. BAC
5. BLK
6. AA
7. RKLB
8. RXRX
9. NOW
10. CAT

Go back to Inovio Pharma (INO) Reports Interim Phase 1 Data For INO-4800 Vaccine for COVID-19

INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19

June 30, 2020 7:30 AM EDT

PLYMOUTH MEETING, Pa., June 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases and cancer, today announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts. In addition, INO-4800 has been selected to participate in a non-human primate (NHP) challenge study as part of the U.S. government's Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective... More